Journal article icon

Journal article

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine

Abstract:

The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a common leukemia-associated mutation in the epigenetic regulator ASXL1. KBM5 cells with CRISPR/Cas9-mediated correction of the ASXL1G710X mutation showed reduced leukemic growth, increased myeloid differe...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s41408-021-00541-0

Authors


Expand authors...
Publisher:
Springer Nature Publisher's website
Journal:
Blood Cancer Journal Journal website
Volume:
11
Issue:
9
Article number:
157
Publication date:
2021-09-21
Acceptance date:
2021-03-16
DOI:
EISSN:
2044-5385
Language:
English
Keywords:
Pubs id:
1196140
Local pid:
pubs:1196140
Deposit date:
2021-09-28

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP